CY1124308T1 - Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak - Google Patents

Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak

Info

Publication number
CY1124308T1
CY1124308T1 CY20211100588T CY211100588T CY1124308T1 CY 1124308 T1 CY1124308 T1 CY 1124308T1 CY 20211100588 T CY20211100588 T CY 20211100588T CY 211100588 T CY211100588 T CY 211100588T CY 1124308 T1 CY1124308 T1 CY 1124308T1
Authority
CY
Cyprus
Prior art keywords
pyrazolylaminobenzimidazole
derivatives
jak inhibitors
compounds
jak
Prior art date
Application number
CY20211100588T
Other languages
English (en)
Inventor
Jolie Anne Bastian
Joshua Ryan Clayton
David Andrew Coates
Daniel Jon Sall
Timothy Andrew WOODS
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1124308T1 publication Critical patent/CY1124308T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του 'τύπου (Ι") πιο κάτω: όπου το R και τα R1-R3 είναι όπως περιγράφεται εδώ, μεθόδους θεραπείας ασθενών για ορισμένα είδη αυτοάνοσων νόσων και καρκίνου. και διαδικασίες παρασκευής των ενώσεων.
CY20211100588T 2016-07-14 2021-07-02 Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak CY1124308T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362208P 2016-07-14 2016-07-14
PCT/US2017/041388 WO2018013486A1 (en) 2016-07-14 2017-07-10 Pyrazolylaminobenzimidazole derivatives as jak inhibitors

Publications (1)

Publication Number Publication Date
CY1124308T1 true CY1124308T1 (el) 2022-07-22

Family

ID=59366549

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100588T CY1124308T1 (el) 2016-07-14 2021-07-02 Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak

Country Status (22)

Country Link
US (2) US10323019B2 (el)
EP (1) EP3484875B1 (el)
JP (1) JP6712331B2 (el)
KR (1) KR102225840B1 (el)
CN (1) CN109476643B (el)
AU (1) AU2017296026B2 (el)
BR (1) BR112018075086B1 (el)
CA (1) CA3030697C (el)
CY (1) CY1124308T1 (el)
DK (1) DK3484875T3 (el)
EA (1) EA038129B1 (el)
ES (1) ES2877198T3 (el)
HR (1) HRP20210965T1 (el)
HU (1) HUE054912T2 (el)
LT (1) LT3484875T (el)
MX (1) MX2019000542A (el)
NZ (1) NZ748942A (el)
PL (1) PL3484875T3 (el)
PT (1) PT3484875T (el)
RS (1) RS61991B1 (el)
SI (1) SI3484875T1 (el)
WO (1) WO2018013486A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230141115A (ko) 2022-03-31 2023-10-10 한림대학교 산학협력단 신규한 2-아릴-1H-벤조[d]이미다졸 유도체, 이의 제조 방법 및 이의 항암제로서의 용도
KR102582097B1 (ko) 2022-12-28 2023-09-25 (주)메디언스 야누스키나아제 표적 억제제 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524911A (ja) * 2007-04-18 2010-07-22 アストラゼネカ アクチボラグ ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
JP5592890B2 (ja) * 2008-10-08 2014-09-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2010068806A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
EA026201B1 (ru) * 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CA2849336A1 (en) * 2011-09-22 2013-03-29 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3715346B1 (en) * 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1

Also Published As

Publication number Publication date
EA201892698A1 (ru) 2019-06-28
BR112018075086A2 (pt) 2019-03-12
CN109476643B (zh) 2021-06-08
EA038129B1 (ru) 2021-07-09
KR102225840B1 (ko) 2021-03-11
EP3484875A1 (en) 2019-05-22
MX2019000542A (es) 2019-07-04
US20180325873A1 (en) 2018-11-15
KR20190015561A (ko) 2019-02-13
CA3030697C (en) 2021-02-23
CN109476643A (zh) 2019-03-15
AU2017296026B2 (en) 2019-11-21
PL3484875T3 (pl) 2021-11-02
HRP20210965T1 (hr) 2021-09-17
JP6712331B2 (ja) 2020-06-17
WO2018013486A1 (en) 2018-01-18
US10344018B2 (en) 2019-07-09
ES2877198T3 (es) 2021-11-16
CA3030697A1 (en) 2018-01-18
NZ748942A (en) 2020-08-28
PT3484875T (pt) 2021-07-05
DK3484875T3 (da) 2021-06-28
LT3484875T (lt) 2021-07-26
SI3484875T1 (sl) 2021-08-31
US20190177300A1 (en) 2019-06-13
JP2019525908A (ja) 2019-09-12
EP3484875B1 (en) 2021-04-07
HUE054912T2 (hu) 2021-10-28
US10323019B2 (en) 2019-06-18
BR112018075086B1 (pt) 2024-02-27
AU2017296026A1 (en) 2018-12-20
RS61991B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
CY1122340T1 (el) Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CY1124749T1 (el) Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
CY1122945T1 (el) Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
MX365590B (es) Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
EA201990400A1 (ru) Соединения и композиции и их применение
CY1121885T1 (el) Αντι-ογκικες ενωσεις
EA201792287A1 (ru) Способы лечения рака
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1124308T1 (el) Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak